Overview

Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis

Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
To evaluate the impact of Lotemax on the initiation of Restasis therapy in patients with dry eye. It is hypothesized that the anti-inflammatory activity of Lotemax may help mitigate the stinging with cyclosporine administration and the dry eye signs and symptoms experienced during the initiation of therapy.
Phase:
Phase 4
Details
Lead Sponsor:
Ophthalmic Consultants of Long Island
Collaborator:
Bausch & Lomb Incorporated
Treatments:
Cyclosporine
Cyclosporins
Loteprednol Etabonate